Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Launched by GUANGZHOU JOYO PHARMA CO., LTD · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new drug called JYP0015 for patients with advanced solid tumors that have specific mutations in a gene called RAS. These tumors can include types of cancer like pancreatic cancer, lung cancer, and colorectal cancer. The main goal of the trial is to see how safe the drug is and whether it can help shrink tumors in adults who have already tried other treatments without success.

To participate in the trial, patients must have a confirmed diagnosis of a solid tumor with a RAS mutation and have experienced disease progression or cannot tolerate previous treatments. They should have a good performance status, meaning they are generally able to take care of themselves. However, patients with certain conditions, such as active brain metastases or severe gastrointestinal issues, may not be eligible. The trial is not recruiting participants yet, but when it begins, those who qualify can expect to receive close monitoring and support throughout their treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
• • 2. Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
• • 3. Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1
• • 4. Adequate organ function
• Exclusion Criteria:
• • 1. Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.
• • 2. Gastrointestinal (GI) disorders that may interfere with drug administration/absorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)
• • 3. Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \<50%.
• • 4. Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.